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Abstract
Background: Intra-articular injection of corticosteroids is used to treat the inflammatory pain of arthritis and osteoarthritis
(OA), but our previous study found a deleterious effect of these steroids on chondrocyte cells. Hyaluronic acid (HA)
injection has been suggested as a means to counteract negative side effects through replenishment of synovial fluid that
can decrease pain in affected joints. To better understand the effects of corticosteroids on these processes,
dexamethasone (Dex) and prednisolone (Pred) were administered to porcine cartilage explants at several concentrations
with and without HA. We examined corticoid effects by determining sulfate-glycosaminoglycan (s-GAG) and uronic acid
(UA) content of the explant media, and safranin-O staining of the cells. Analysis of lactate dehydrogenase (LDH) activity
was conducted to assess cell cytotoxicity.
Results: Dex treatment significantly reduced cellular cytotoxicity compared to the other treatment groups, especially
with regards to the release of s-GAG, and protects against superficial proteoglycan damage. However, there was no
difference between Pred and Dex, with and without HA, in the UA content remaining in porcine cartilage explants.
Conclusions: The data suggest that combinations of Dex and Pred with HA did not have a significant effect on
protection or enhancement of the articular cartilage matrix under the current conditions.
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Background
Osteoarthritis (OA) is a degenerative disease that affects
the functional ability of movable joints. Progression of
the disease not only leads to degeneration of the articu-
lar cartilage, but also affects the entire synovial joint
complex, including the subchondral bone, joint capsule,
ligaments, tendons, synovial membrane, and menisci [1].
A number of factors, such as environment, genetics, as
well as changes in the metabolism of the joint tissues
can affect the degeneration and progression of cartilage
lesions [2, 3]. The predominant symptoms of OA are
pain, stiffness, and functional limitation of the joint.
Interventional treatments using pharmacological therap-
ies that are concurrent with physiotherapy provide
symptomatic relief and aids physical therapy effective-
ness [4].
Intra-articular (IA) injections of corticosteroids are
often used in relieving pain via inhibition of the accumu-
lation of inflammatory cells and mediators [5, 6]. The
most common anti-inflammatory corticosteroids in vet-
erinary medicine for relief of pain are dexamethasone
(Dex) and prednisolone (Pred) [7]. Both are effective
against inflammatory diseases and act by inhibiting in-
flammatory agents, such as PGE2 [8] and interleukin-1β
[9]. IA injections of Dex or Pred are recommended in
OA therapy because of their proven effectiveness in
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controlling chronic inflammation and pain [8–10]. How-
ever, many studies have shown that long-term IA cor-
ticosteroid injections have adverse effects, including
enhanced progressive damage and increased risk of joint
destruction. These events are brought on through de-
creased chondrocyte proliferation, induced cell apop-
tosis, and extracellular-matrix formation [11, 12],
together with cartilage degeneration [12–14].
Hyaluronan (HA), or hyaluronic acid, is composed of
repeating sequences of disaccharides, glucuronic acid,
and N-acetylglucosamine. Intra-articular injections of
HA are given to restore the viscoelasticity of the synovial
fluid by inducing synoviocytes and chondrocytes to
synthesize natural HA and inhibit the degradation of en-
dogenous HA [15–18]. This is well documented in hu-
man and animal studies: injections have been shown to
decrease pain and improve functional outcomes in OA
as well as decrease inflammation in the joints [15–20].
However, the combined effect of steroids and local
HA on chondrocytes has not been studied. Thus, the
present study was conducted to determine if the sim-
ultaneous use of HA and corticosteroids (Dex and
Pred) could reduce the adverse effects of corticoste-
roids on the biochemical properties of porcine cartil-
age explants in vitro.
Methods
Sample population
Normal porcine articular cartilage specimens (no
osteoarthritis lesions) were prepared from the carpal
and the tarsal joints of pigs that were ~20–24 weeks
old (n =16), using an aseptic technique. The joints
were received from a local slaughter house and proc-
essed within 6 h after slaughter, as described before
[21]. The methods were carried out in accordance
with the approved guidelines. The experimental
protocol was approved (2014) by the Scientific and
Ethics Committee, Faculty of Veterinary Medicine,
Chiang Mai University, Chiang Mai Thailand.
Reagents
Low molecular weight HA for IA injection (~500–
730 kDa) was obtained from TRB Chemedica (Bangkok,
Thailand). HA was diluted with Dulbecco’s modified Ea-
gle’s medium (DMEM, Gibco Life Technologies) without
serum and used for the experiment at the final concen-
tration of 2.5 mg/ml. Three different concentrations
(12.5 %, 25 %, and 50 %, respectively) of each of the
drugs, Pred (L.B.S. Laboratory, Bangkok, Thailand) and
Dex (T.P. Laboratories, Bangkok, Thailand), were estab-
lished from the stock concentration of the drugs and di-
luted with serum-free DMEM (end concentrations: Pred
at 3.125 mg/ml, 6.25 mg/ml, and 12.5 mg/ml, and Dex
at 0.5 mg/ml, 1.0 mg/ml, and 2.0 mg/ml).
Porcine cartilage explant cultures and experimental
designs
Porcine cartilage explant cultures
The explants were prepared following the method of
Chaiwongsa [21]. In brief, the joints were opened asep-
tically and pieces of cartilage were sliced from the con-
dyles of the carpal and the tarsal joints; the average size
of these pieces was ~7-8 mm long by ~1.5-2 mm deep
and by ~2-4 mm wide. All of the explants were washed
once with 70 % ethanol for 30 s, followed by washing
three times with sterile phosphate buffered saline (PBS).
Three pieces of the explants were placed into wells
(~30–35 mg/well) of sterile 24-well culture plates. The
cartilage disks were then incubated in 1000 μl serum-
free DMEM until the start of the experiment, within
24 h. To investigate the effect of Dex and Pred com-
bined with HA, the cartilage disks were cultured in
serum-free DMEM (negative-control) that contained 200
units/ml of penicillin, 200 μg/ml of streptomycin, and
50 μg/ml of gentamicin. Treatment groups were inocu-
lated with serum-free DMEM containing varying con-
centrations of Dex or Pred co-treated with or without
HA to create 14 treatment groups in replication of three.
Then, the cartilage disks were further incubated for
14 days as described below.
Experimental design
The experimental design of the porcine cartilage explant
treatments is presented in Table 1. All cultures were main-
tained at 37 °C under 5 % CO2. The conditioned media
were collected immediately before treatment (day 0) and
14 days after treatment. The cconditioned media and the
cartilage explant disks were harvested and stored at −20 °C
until further analysis. The cell cytotoxicity was measured
Table 1 Experimental group in this study
Control groups
Name Condition
Control DMEM without serum
HA HA 2.5 mg/ml
Treatment groups
Pred Dex
Name Condition Name Condition
Pred50 Pred 50 % Dex50 Dex 50 %
P50 + HA Pred 50 % with HA
2.5 mg
D50 + HA Dex 50 % with HA
2.5 mg
Pred25 Pred 25 % Dex25 Dex 25 %
P25 + HA Pred 25 % with HA
2.5 mg
D25 + HA Dex 25 % with HA
2.5 mg
Pred12.5 Pred 12.5 % Dex12.5 Dex 12.5 %
P12.5 +
HA




Dex 12.5 % with HA
2.5 mg
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based on the level of enzyme lactate dehydrogenase (LDH)
in the conditioned media. The conditioned media and the
cartilage explant disks were assayed for the release of bio-
molecules through cartilage matrix degeneration assay.
Additionally, the cartilage explant disks were examined for
the purpose of histopathology observation.
Cytotoxicity assay
Lactate dehydrogenase (LDH) assay
The toxicity effect of all treatment conditions on the via-
bility of chondrocytes within the explant disks was de-
termined by colorimetric assay of LDH activity in the
culture media [22]. The conditioned media of the cartil-
age explants disks were examined using CytoTox 96®
Non-Radioactive Cytotoxicity Assay (Promega, USA) ac-
cording to the manufacturer’s instructions and by com-
paring with the untreated media.
Determination of cartilage matrix degradation
Sulfated glycosaminoglycan (s-GAG) content
The degradation of s-GAG was determined by meas-
uring the s-GAG quantity in the culture media,
which indicated biochemical changes in the articular
cartilage. The S-GAG concentration was measured
using a colorimetric dye (dimethylmethyleneblue
[DMMB]) binding assay that was modified from a
previous study [23]. Briefly, chondroitin 6-sulfate
from shark cartilage (CS-C) (Sigma-Aldrich, USA)
was used as the standard, with concentration values
ranging from 0 μg/ml to 100 μg/ml. CS-C standards
or diluted media samples (50 μl) were pipetted into
96-well plates. Then, 200 μl of the DMMB dye solu-
tion was immediately added to each well. Serum-free
media was used as the blank. The absorbance of the
solution was immediately measured at 540 nm using
a microplate reader spectrophotometer and concen-
trations of s-GAG calculated [24].
Quantification of uronic acids (UA)
UA is a component of hyaluronic acid and chondro-
itin sulfate in the cartilage matrix, and was measured
using a colorimetric assay: the carbazole analysis was
modified according to the method discussed by
Cesaretti [25]. Treated cartilage disks were digested
with 200 μl of papain, 2 units, at 60 °C for ~48 h,
and papain cartilage-digested media was diluted with
distilled water at 1:5. Glucuronolactone was used as
the standard reagent. A volume of 50 μl of diluted
digested sample, or standard, was added with 300 μl
of borate/sulfuric acid reagent (0.025 M Na2B4O7 in
conc. sulfuric acid). Thereafter, the samples were
heated at 100 °C for 15 min. When the sample
cooled down to room temperature, carbazole in
ethanol was added. After heating at 100 °C for
~15 min and cooling down to room temperature
again, the quantity of uronic acid in the sample was
measured at 540 nm, and the uronic acid content
was estimated from the following calculation:
UA content %μg=mg of dry tissueð Þ
¼ 100 UA Day 14 treated sample=weight of dry tissueð Þ
Histopathology study
The cartilage disks were fixed in 10 % neutral buffer
formalin and subsequently embedded in paraffin
wax. Cartilage sections of approximately 6 μm were
prepared. The sections of each sample were stained
with common haemotoxylin and eosin (H&E) and
safranin-O, the latter of which is used to determine
the proteoglycan content. Then, the cartilage sec-
tions were imaged by a Biocom microscope using an
AxioCam camera (Carl Zeiss, Germany). The H&E
stained samples were graded and given scores for
the cartilage structure, which was followed by chon-
drocyte pathology according to the recommended
protocol of the OARSI histopathology initiative [26].
The intensity of safranin-O staining of cartilage sec-
tions was used to quantify the proteoglycan content
[27]. These were done by processing and calculating
the stained image using ImageJ [28] 1.47 morpho-
metric computer software (Wayne Rasband, National
Institute of Health, USA).
Statistical analysis
Values were expressed as mean ± standard deviation
(S.D.) and the data analyzed using SPSS program version
17 for the Windows software package. Significant differ-
ences among treatment groups, except for histopath-
ology data, were determined using one-way analysis of
variance (ANOVA) at a significance level of p < 0.05. Dif-
ferences in grades of histopathology staining were deter-
mined using the Kruskal–Wallis test.
Results
Effect of steroids in combination with HA on cell
cytotoxicity in cartilage explant culture systems
Cytotoxicity tests were conducted to evaluate the ef-
fect of steroids on porcine chondrocytes in cartilage
explant culture systems. After treatment of the cartil-
age disks with steroids with and without HA, an ana-
lysis of LDH content was carried out using an LDH
activity assay. The release of LDH into the culture
medium from the damaged cells (cell loss of integrity)
indicated an inclination toward cell death. The LDH
content increased gradually in the Pred-treated groups
from 50 %, 25 %, and 12.5 % concentrations (Fig. 1).
At the same time, a significant inverse trend (de-
crease) was observed for the combination of Pred
Siengdee et al. BMC Veterinary Research  (2015) 11:298 Page 3 of 11
and HA, starting from P50 + HA, compared with the
Pred-treated groups, with a marked decrease in P25 +
HA and P12.5 + HA, compared with Pred50 + HA
(p<0.05), which had slightly lower LDH content than
the control and the HA groups (p>0.05). For Pred
12.5, the HA co-treatment reduced the cytotoxicity of
the chondrocytes in the system at p<0.05 (from
136.28 % to 92.40 %, relative to the control group).
However, no difference in LDH content between all
of the Pred-treated groups and the control/HA
treated group was found (p>0.05). For the Dex-
treated group, a significant difference was found be-
tween both the Dex-treated and the Dex + HA-treated
groups when compared with the control, the HA
group, and all Pred-treated groups (p<0.05). Neverthe-
less, there were no significant differences found be-
tween the Dex-treated groups and the Dex + HA-
treated groups in LDH content (Fig. 1). Notably, the
mean percentage of the LDH content was reduced
(p<0.05) in all the Dex and the Dex + HA treatment
groups (8.80–14.72) in comparison with the control
group, which was set as 100.
Effects of Pred and Dex in combination with HA on
release of s-GAG
The in vitro effects of HA in combination with Pred and
Dex treatment on cartilage explant disks are shown in
Fig. 2. At the end of the experiment, the culture media
was evaluated for s-GAG which is the carbohydrate part
of the aggrecan molecule and is a marker of cartilage
degradation. The result showed a significant increase
in the levels of s-GAG in the culture media of all HA
and HA combination groups in comparison with the
control. All of the Pred-treated groups at doses of
50 %, 25 %, and 12.5 % increased the release of s-
GAG compared with the untreated group, but still in-
creased the s-GAG level when compared with the sin-
gle HA-treated group (p<0.05). Dex treatment
protected against the release of s-GAG into the cul-
ture media, compared with the control (p<0.05) and
HA-treated groups. Surprisingly, at lower concentra-
tions, Dex was more effective than Pred against the
release of s-GAG (p<0.05).
Pred and Dex increase UA content from cartilage tissues
We next determined the UA content, which is a
class of monosaccharide derivative monomers of the
glycosaminoglycans of proteoglycans and HA, using
the DMB assay and results are shown in Fig. 3. The
percentages of UA content in most of the steroid-
treated groups (except Pred12.5 and single HA-
treated groups) were significantly higher when com-
pared with those of the control and the HA-treated
group (p<0.05). Comparing the control and the single
HA-treated groups, a slight improvement in the UA
content was observed in the HA treatment (p<0.05).
Fig. 1 The effect of Pred and Dex in combination with HA on cell cytotoxicity. The LDH content of the cartilage explant treatments was calculated and
compared with the control group. After the 14-day treatment period, the culture media were analyzed for LDH release, as previously described. The results
are expressed as a percentage relative to the control group. The white bar denotes the control; the light gray bars denote the HA-treated or the co-treated
groups; and the dark gray bars denote the steroid-treated groups. The data are expressed as the mean ± SD (n= 3). Significant differences are considered
to exist when p< 0.05: “a” stands for significant differences compared with the control group; “b” denotes significant differences compared with HA; dagger
(‡) stands for significant differences compared with all Pred-treated groups; and asterisk (*) denotes significant differences between the treatment groups
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Of these, the most effective working concentration
was found to be the 25 % treatment in both Pred and
Dex because it significantly increased the UA content
in cartilage explant disks compared to the control
and the other treatment concentrations (p<0.05). In
this study, co-treatment of HA could not be
attributed to UA preservation; in addition, the co-
treatment of HA at Dex25 (Dex25 + HA) could not
counteract the destructive effects of Dex nor signifi-
cantly lower the content of UA in the explants when
compared with the Dex25-treated group (p<0.05).
Overall, comparing between the Pred and the Dex
Fig. 2 The effect of Pred and Dex in combination with HA on the release of s-GAGs. The percentage of the s-GAG content in the cartilage explant
treatments was calculated and compared with that of the control group. After 14 days of treatment, the culture media were analyzed for the
s-GAGs released into the media. The results are expressed as a percentage relative to the control. The white bar denotes the control; the light
gray bars denote HA-treated or the co-treated groups; and the dark gray bars denote the steroid-treated groups. The data are expressed as the
mean ± SD (n = 3). Significant differences are considered to exist when p < 0.05: “a” stands for significant differences compared with the control
group; “b” denotes significant differences compared with the HA group; dagger (‡) stands for significant differences compared with all the
Pred-treated groups; and asterisk (*) denotes significant differences between the treatment groups
Fig. 3 The percentage of uronic acid (UA) content patterns of steroids in combination with the HA treatment. The UA content of the cartilage explant
treatments was calculated and shown in % μg/mg of dry tissue. The white bar denotes the control group; the light gray bars denote the HA-treated or
the co-treated groups; and the dark gray bars denote the steroid-treated groups. Error bar: standard deviation of each group (n= 3 for each group).
Significant differences are considered to exist when p< 0.05:“a” stands for significant differences compared with the control group; “b” denotes significant
differences compared with the HA group; and asterisk (*) denotes significant differences between the treatment groups
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treatments, Dex appeared to be more effective in im-
proving both the s-GAG release and the UA content
that remained in the cartilage disks.
Histological analysis
Results of histological analysis of cartilage explant-disks
after 14 days of Pred and Dex treatment in combination
with HA are shown in Fig. 4. Cartilage disk sections
were stained with safranin-O to identify proteoglycan
content. A significant increase in safranin-O staining
was observed in the steroid-treated cartilage disks com-
pared to controls, indicating that the treatments with
Pred and Dex had enhanced the proteoglycan content in
the matrix of the explant cultures or inhibited the cartil-
age destruction. We found that the superficial zone in
nearly every treatment group, including the control and
Fig. 4 Histological staining with safranin-O (×100) of conditioned porcine cartilage disks. After 14 days of treatment with various concentrations of
corticosteroids in combination with HA, the proteoglycans content in the cartilage tissue stains is indicated by safranin-O staining. The extent of the
morphological change and the proteoglycans content were compared between all of the treatment groups. (a) Safranin-O staining representative of the
results are shown start from upper row and left to right: control, HA, Pred50, Pred25, Pred12.5, P50 +HA, P25 +HA, P12.5 + HA, Dex50, Dex25, Dex12.5 and
the last row D50 +HA, D25 +HA, D12.5 + HA, respectively. The Dex and the HA-treated groups performed rather efficiently, as indicated by the intense red
hue, better than the other groups, including the control. The scale bars represent 100 μm. (b) An increase in the safranin-O intensity (relative to the control)
in the steroid treatment groups is shown in the bar chart which is exhibited as the mean ± SD of the triplicate independent. Significant differences are
considered to exist when p< 0.05: “a” stands for significant differences compared with the control group; “b” denotes significant differences compared with
the HA group; dagger (‡) stands for significant differences compared with all the Pred-treated groups; hash (#) denotes significant differences compared
with all the Dex-treated groups; and asterisk (*) stands for significant differences between the treatment groups
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the HA groups, exhibited faded safranin-O intensity.
Subsequently, the images were processed using the
ImageJ analysis program, and plotted as a bar chart
(Fig. 4b). The major increase in intensity was found
in the co-treatment Pred25 + HA group, and was
higher than that of the controls (p = 1.137 × 10−12).
Moreover, the groups that underwent Dex treatment
produced better results in proteoglycan content pres-
ervation when compared with the Pred-treated
groups (p = 1.136 × 10-12 ,0.05 and 2.015 × 10−08 at
50 %, 25 %, and 12.5 % concentrations, respectively).
Results of H&E staining to identify cell morphology,
matrix structure, and composition in the treated ex-
plants are shown in Fig. 5. The morphology of the
chondrocytes that were embedded in the treated car-
tilage explants was evaluated. Fibrillation on the ar-
ticular surface and the chondrocyte characteristics,
such as cell cluster formation and chondrocyte clon-
ing and empty lacuna were considered. Nevertheless,
the grading scores of the chondrocyte characteristics
of the HA-treated group and those of the combin-
ation treatments with both Pred and Dex at 12.5 %
and 25 % revealed slight differences (grade 1) in
comparison with the other groups (normal, grade 0).
Discussion
The pathogenesis of OA is caused primarily by an
imbalance in joint metabolism; for example, when ca-
tabolism exceeds anabolism, which leads to degrad-
ation of the cartilage matrix [29]. Progressive cartilage
loss makes the cartilage lose its normal shape, which
leads to progressive painful and functional impair-
ment [1]. Current therapeutic treatment options for
OA are aimed at reducing pain, improving joint func-
tion, and limiting progressive cartilage loss, all of
which are intended to maintain a good quality of life.
However, medications used in the management of OA
need to take into consideration possible side effects
that bring about further deterioration of the articular
cartilage. Traditionally, IA injections of corticosteroids
have been used concurrently to provide short-term
pain relief for patients with degenerative joints via
inhibiting the accumulation of inflammatory cells and
mediators, thereby subsequently decreasing swelling,
diminishing pain, and improving motion [5, 6, 30]. In par-
ticular, IA corticosteroid injections for OA have proven ef-
fective for chronic pain management and preventing the
progression of cartilage degeneration in the early stages of
OA, and are recommended when signs of local
Fig. 5 The histological section of porcine cartilage explants following 14 days of treatment with different and various concentrations of
corticosteroids in combination with HA: H&E. The articular cartilage showing both the regular and the irregular cell clusters (H&E staining, 100×).
The scale bars represent 100 μm
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inflammation arise [31, 32]. They are especially useful in
patients who have not had success with NSAIDs or cannot
use them because of gastrointestinal side effects. Neverthe-
less, derivatives of corticosteroids have been reported to
have cytotoxic effects on various cell types, including chon-
drocyte cells. These side effects include inhibition of chon-
drocyte cell growth and induction of cell apoptosis [11–14],
resulting in the loss of extra-cellular matrix formation and
progressive degradation of the articular cartilage [12]. How-
ever, there are reports that corticosteroids do not directly
cause chondrocyte death, but rather the effect is due to
the presence of the preservative agent, benzalkonium
chloride, in the injectable suspension [33]. Alternatively,
supplementary HA injection has been recommended for
OA for pain relief and improved joint function [32, 34, 35],
although its effects on articular cartilage have not been
clearly established [31, 36]. More recently, treatment
strategies using corticosteroids in combination with
HA injections have been shown to improve both pain
and joint function, and are superior to treatment with
HA alone [34, 37].
In our study, we used normal porcine cartilage ex-
plants as an in vitro model for examining the direct ef-
fects of the most commonly used corticosteroids, Dex
and Pred, in addition to subsequent co-culturing with
HA combinations on the articular cartilage. We com-
pared the in vitro extracellular matrix molecules, cell
cytotoxicity, and morphologic changes of the porcine ar-
ticular cartilage explants after exposure to corticosteroid
and HA. The experiment was designed for clinical appli-
cation by avoiding external serum growth factor condi-
tions that are associated with the cartilage extracellular
matrix composition and cellularity changes [38] and ex-
cessive cell proliferation [39]. As a result, the culture
medium was changed from supplementary 10 % to
serum-free when the treatment was initiated, and the
serum-free medium was used for the control group.
There are no reports of using these steroids in an
in vitro cartilage explant model, so doses were chosen
that represented two-fold serial dilutions of commer-
cially available stock preparations. The concentration
of HA was chosen based on a previous study of
Euppayo [40]. The study duration of 14 days of por-
cine cartilage explant culture is the maximum dur-
ation recommended for cartilage graft storage, as
mentioned in Pallante [41]. Based on the LDH assay
results, cytotoxic effects were observed after Pred
treatment at the highest concentration (50 %, or
2.0 mg/ml). In the combination treatment, however,
inclusion of HA reduced the Pred cytotoxic effects
and exhibited a protective effect when compared with
the control and HA-only treated groups, while the
Dex treatment groups dramatically decreased cell
cytotoxicity in explant models when compared with
others. Remarkably, this is inconsistent with the findings
of previous studies. Dex has been found to induce cell
death and suppress cell proliferation in cell types of many
species, including chondrocytes and tendon cells, even at
lower concentrations [11, 42, 43]. The results also
contrasted with our preliminary study using a mono-
layer culture, where there was trend towards chon-
drocyte cell death in human articular cartilage in
accordance with Dex concentration, whereas Pred
treatment had little effect [44]. A determination of
cartilage matrix degradation in both s-GAGs released
and UA content that remained in the cartilage disks
was carried out. Dex was found to be extremely effec-
tive—much more than Pred—against s-GAG loss and
highly efficient in enhancing UA content in the cartil-
age explant disks compared with the control. Of
these, the most effective concentration of Dex was
found to be 25 %.
Safranin-O staining intensity is representative of the
amount of proteoglycan remaining in the cartilage disks.
In this context, the Dex50-treated groups were observed
to have safranin-O dark stains, which refers to all of the
proteoglycans remaining in the matrix, whereas at the
superficial zone in the control, HA treatment and Pred-
treatment groups, the safranin-O intensity was faded,
implying the loss of some proteoglycan. Culture condi-
tions in this study were similar to those in the study of
Moo [45] in bovine articular cartilage. Scientific findings
for the application of cartilage explants revealed that the
proteoglycan content insignificantly decreased gradually
over time in long-term culture until 17 days [45], and a
variety of matrix content changes in the superficial zone
was measured under various culture conditions [41, 46].
These occur together through peripheral collagen net-
work degradation [45, 47]. Some changes were observed
in the H&E histological results in groups of single/com-
bination with HA treatments. Cartilage-treated speci-
mens were observed to present the occurring of minor
clusters of cell dispersing in the OA articular cartilage.
The clusters arose due to the uniformity in the extracel-
lular matrix of the cartilage, which is associated with
some degree of cell death [48].
The results of cell cytotoxic effect and cartilage
matrix degradation investigation were consistent in
this study, but did not support our hypothesis that
HA would be protective against the negative side ef-
fects of corticosteroid treatment. Rather HA combina-
tions showed more destructive effects and did not
cause significant enhancement of the articular cartil-
age matrix when exposed to corticosteroid alone and
the control group, in particular, the Dex treatment.
However, it was found that co-treatment of HA with
Pred was successful in reducing the cytotoxic effects
of this drug.
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Currently, two molecular weights of HA, low
(500–730 kDa) and high (6–7 million Da), are avail-
able, and each displays distinct pharmaceutical ef-
fects [35]. High molecular weight hyaluronic acid
preparations are highly effective in relieving pain and
have greater anti-inflammatory activity in vivo [35],
while low molecular weight HA is similar to native
hyaluronic acid. In particular, low molecular weight
HA has shown impressive effects in many in vitro
studies [49] in terms of activated proliferation and matrix
synthesis [50], and reduced apoptosis of chondrocytes by
inhibiting two specific receptors: anti-CD44 and anti-
ICAM-1 [51]. Nevertheless, the effects of HA treatment
are dependent on its molecular weight, concentration, and
application duration [36, 52], in regards long-term pain re-
lief [32, 34, 53]. The HA effects observed in this study are
different from those observed in many previous clinical
studies [32, 34, 53]; this could be because of the limited
drug exposure duration in these culture systems, which
resulted in limitations in the determination of the
HA-treatment effects. There also could be differ-
ences due to in vitro vs. in vivo model systems, the
latter of which involves more complex interactions
between adjacent tissues of the joints. Last, it could
be the result of low molecular weight of HA having
more adverse effects, resulting in changes in the
downstream signaling modification in the disease
process, as discussed and reviewed elsewhere [35, 52,
54–56].
Overall, when a comparison is made between Pred and
Dex treatments, Dex scores distinctively better in the ac-
tion against s-GAG degradation and improvement in the
UA content remaining in cartilage disks; it might also im-
prove cell cytotoxicity in the culture condition. In com-
bination with the findings of previous preliminary studies,
it can be concluded that short-term Dex treatment is ef-
fective in suppressing the catabolic activities of pro-
inflammatory cytokines by inhibiting the phospholipids,
together with preventing proteoglycan degradation and re-
storing the matrix production [30, 46, 57, 58]. This is simi-
lar to observations in the culture systems of human and
bovine bone marrow stromal cells [59]. Hence, it is specu-
lated that besides its excellent anti-inflammatory effect,
Dex may play a role in maintaining the mechanical func-
tions as well as enhancing the matrix formation and the
functional properties of articular cartilage.
Some limitations of this research must be considered.
First, we were limited in the duration to which the ex-
plants were exposed to the drug treatment; therefore, the
results might not reflect the complex effects in compari-
son with in vivo or clinical trials. Second, we utilized a sin-
gle concentration of HA-treated combinations and chose
to select the most commonly used glucocorticoids agents.
In this regard, based on other reports and our previous
preliminary data, different variations and combinations of
HA treatment as well as the direct effects of Pred and Dex
in chondrocytes should be subjected to further in-depth
evaluation.
Conclusions
These findings provide basic knowledge on the efficacy
of selected corticosteroids to treat articular cartilage
damage and prevent of the same via use of these drugs
in combination; the consequences of the treatment
point to the possibility for application of these mechan-
ical effects in the clinical environment. Results from this
study indicate that Dex is an effective drug that has
rehabilitation possibilities in the treatment of OA and
may be efficacious in protecting against the loss of
glycosaminoglycan molecules without causing chondro-
cyte cell death. Additionally, HA combinations have not
been completely elucidated and are still a matter of con-
cern. We suggest that if this combined treatment cannot
be avoided, then an appropriate treatment duration
should be provided.
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